- Home
- IKNA vs INCR Comparison
IKNA vs INCR Comparison
Compare IKNA & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- INCR
- Stock Information
- Founded
- IKNA 2016
- INCR 1994
- Country
- IKNA United States
- INCR Israel
- Employees
- IKNA N/A
- INCR N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- INCR Health Care
- Exchange
- IKNA Nasdaq
- INCR Nasdaq
- Market Cap
- IKNA 64.7M
- INCR 76.7M
- IPO Year
- IKNA 2021
- INCR N/A
- Fundamental
- Price
- IKNA $1.32
- INCR $1.41
- Analyst Decision
- IKNA Buy
- INCR
- Analyst Count
- IKNA 2
- INCR 0
- Target Price
- IKNA $3.00
- INCR N/A
- AVG Volume (30 Days)
- IKNA 84.4K
- INCR 16.0K
- Earning Date
- IKNA 03-06-2025
- INCR 04-08-2025
- Dividend Yield
- IKNA N/A
- INCR N/A
- EPS Growth
- IKNA N/A
- INCR N/A
- EPS
- IKNA N/A
- INCR N/A
- Revenue
- IKNA N/A
- INCR $72,420,918.00
- Revenue This Year
- IKNA N/A
- INCR N/A
- Revenue Next Year
- IKNA N/A
- INCR $39.30
- P/E Ratio
- IKNA N/A
- INCR N/A
- Revenue Growth
- IKNA N/A
- INCR N/A
- 52 Week Low
- IKNA $1.22
- INCR $1.17
- 52 Week High
- IKNA $1.94
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- IKNA 43.56
- INCR 31.26
- Support Level
- IKNA $1.27
- INCR $1.37
- Resistance Level
- IKNA $1.43
- INCR $1.48
- Average True Range (ATR)
- IKNA 0.07
- INCR 0.06
- MACD
- IKNA 0.00
- INCR -0.01
- Stochastic Oscillator
- IKNA 37.21
- INCR 15.94
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.